单次就诊4部位皮内狂犬病加强接种在基础免疫5年后诱导稳健免疫应答
基于菲律宾一项随机对照研究(NCT01622062)的5年随访,比较1周4部位皮内(4-4-4-0-0)方案与更新版泰国红十会28天2部位方案的持久免疫原性。结果显示4部位方案组抗体滴度更高、血清保护比例更持久,第5年模拟暴露后单次就诊4部位皮内加强接种可快速诱导回忆应答,所有参与者抗体均达保护水平。
要点
- 1周4部位皮内方案在基础免疫后5年抗体滴度持续高于2部位方案。
- 第5年模拟暴露后单次就诊4部位皮内加强接种,所有参与者第11天抗体≥0.5 IU/mL。
- 随访及模拟暴露接种期间未发现安全性问题。
核心结论
- 缩短的1周4部位皮内方案比更新版2部位方案获得更持久的高抗体滴度和血清保护。
- 单次就诊4部位皮内模拟暴露后接种可快速诱导回忆应答,提示稳健保护。
研究设计与样本
- 随机对照研究(NCT01622062)的5年随访及模拟暴露后接种分析,共397名参与者。
- 比较三组:无免疫球蛋白的4部位皮内组(Group 1)、加马源免疫球蛋白的4部位皮内组(Group 2)、加马源免疫球蛋白的2部位皮内组(Group 3)。
主要发现
- 年度随访血清转换率(RVNA≥0.5 IU/mL)Group 1持续>95%,Group 2稳定在80-90%,Group 3从80%降至64%。
- Group 1的RVNA几何平均滴度持续高于其他两组,Group 3通常最低。
- 第5年模拟暴露后接种,所有组均出现明显回忆应答,第11天所有参与者RVNA≥0.5 IU/mL。
关键数值与推荐
- 血清转换定义为RVNA滴度≥0.5 IU/mL,采用快速荧光灶抑制试验(RFFIT)检测。
- Group 1年度随访血清转换率>95%,Group 2为80-90%,Group 3从80%降至64%。
临床怎么用
- 对于完成1周4部位皮内基础免疫者,5年后单次就诊4部位皮内加强接种可快速提供保护。
- 该方案可能简化暴露后加强接种流程,减少就诊次数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a randomized controlled study (NCT01622062) a 1-week, 4-site intradermal (ID, 4-4-4-0-0) post-exposure prophylaxis (PEP) rabies vaccination regimen with purified Vero cell rabies vaccine (PVRV, Verorab®, Sanofi Pasteur), either without (Group 1) or with (Group 2) purified equine rabies immunoglobulin (ERIG), patients in the Philippines achieved seroconversion rates at Day 14 that were non-inferior to that of the updated Thai Red Cross (TRC) 28-day, 2-site (2-2-2-0-2) ID regimen with ERIG (Group 3). Presented here are the annual immunogenicity data up to five years after the last primary dose, and the immunogenicity and safety data following simulated PEP with single-visit, 4-site ID regimen. METHODS: Rabies virus neutralizing antibodies (RVNA) were determined by rapid fluorescent focus inhibition test (RFFIT). Participants (n = 397) received simulated PEP vaccination ID at Year 5 and RVNAs were assessed at Day 11 post-vaccination. RESULTS: Seroconversion rates (RVNA titres ≥ 0.5 IU/mL) during annual follow-up remained >95% in Group 1 and were relatively stable at 80-90% in Group 2, but decreased from 80% to 64% in Group 3. RVNA geometric mean titres (GMTs) in Group 1 were consistently higher than in the other two groups, and those in Group 3 were generally lower than in the other two groups. There was a clear anamnestic response to vaccination in all groups, with all participants achieving RVNA titres ≥ 0.5 IU/mL at Day 11 post-simulated PEP booster vaccination. There were no safety concerns raised during annual follow-up and with simulated post-exposure vaccination with PVRV. CONCLUSION: The shortened, 1-week, 4-site ID regimen with PVRV achieved persistently higher RVNA titres than the updated 2-site TRC regimen, and more participants remained seroprotected up to five years after the last dose of primary immunization. Simulated post-exposure with 4-site ID rapidly induced an anamnestic response indicative of robust protection.
引用
- Quiambao BP, Ambas C, Diego S, et al. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines. Vaccine. 2020. PMID: 32280042. doi:10.1016/j.vaccine.2020.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。